Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis

Fig. 2

OS depending on the EGFR status stratified by the presence of LM. a A subanalysis was performed selecting those patients with liver involvement. We observed a significant difference between those patients harboring EGFR mutations (n = 9) compared to those showing wild-type EGFR (n = 46). b When selecting patients with no liver involvement, we also observed a better outcome for those harboring EGFR mutation (n = 21) compared to those with EGFR wild type NSCLC (n = 98).

Back to article page